In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The association between implantable defibrillators and all-cause mortality in left ventricular assist device carriers - initial results of a propensity score adjusted analysis

Session Patient management - From oral treatment to transplant

Speaker Assistant Professor Maja Cikes

Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Ventricular Assist Devices
  • Session type : Rapid Fire Abstracts
  • FP Number : 1549

Authors : M Cikes (Zagreb,HR), N Jakus (Zagreb,HR), JJ Brugts (Rotterdam,NL), P Rubis (Krakow,PL), G Burneikaite (Vilnius,LT), E Van Craenenbroeck (Antwerp,BE), AC Pouleur (Brussels,BE), E Barge-Caballero (A Coruña,ES), A Gkouziouta (Athens,GR), D D'amario (Rome,IT), S Grundmann (Freiburg-Bad Krozingen,DE), LH Lund (Stockholm,SE), A Flammer (Zurich,CH), D Milicic (Zagreb,HR), F Ruschitzka (Zurich,CH)


M Cikes1 , N Jakus1 , JJ Brugts2 , P Rubis3 , G Burneikaite4 , E Van Craenenbroeck5 , AC Pouleur6 , E Barge-Caballero7 , A Gkouziouta8 , D D'amario9 , S Grundmann10 , LH Lund11 , A Flammer12 , D Milicic1 , F Ruschitzka12 , 1University of Zagreb School of Medicine, Department of Cardiovascular Diseases - Zagreb - Croatia , 2Erasmus Medical Center - Rotterdam - Netherlands , 3John Paul II Hospital - Krakow - Poland , 4Vilnius University Hospital - Vilnius - Lithuania , 5University Hospital Antwerp - Antwerp - Belgium , 6Cliniques Saint-Luc UCL, Division of Cardiology - Brussels - Belgium , 7Hospital Universitario de A Coruña - A Coruña - Spain , 8Onassis Cardiac Surgery Center - Athens - Greece , 9Catholic University of the Sacred Heart - Rome - Italy , 10Universitäts-Herzzentrum - Freiburg-Bad Krozingen - Germany , 11Karolinska Institute, Department of Medicine - Stockholm - Sweden , 12University Hospital Zurich, Clinic for Cardiology - Zurich - Switzerland ,

On behalf: The PCHF VAD-ICD/CRT Registry


Introduction: The role of multiple devices frequently implanted in patients with advanced heart failure requires further insight from diverse patient cohorts. We have formed a registry of ventricular assist device (VAD) carriers through a network of European heart failure centres, aiming to investigate the association between implantable defibrillator and all cause death in VAD recipients. 

Methods: At current, the registry includes data on 246 patients with continuous flow LVADs (median age 56 (IQR 48-63), 83% male), 63% of which also received an ICD or CRT-D. We created a propensity score to determine the possibility of having an ICD/CRT-D. This was followed by a propensity score adjusted analysis to assess the relation of ICD or CRT-D device carrier status and the occurrence of the primary event of all-cause death. The median follow-up time was 1.3 years (IQR 0.4-2.0) from index date, defined as time of LVAD or ICD/CRT-D implant, whichever came later.

Results: The baseline characteristics varied significantly according to ICD/CRT-D carrier status (Table 1). The rate of all-cause death was significantly lower in ICD/CRT-D carriers (14.0 (9.8-19.9) vs 31.6 (22.8-43.8) per 100 patient-years) as was the crude hazard ratio for all-cause death (0.43 (0.27-0.71), p=0.001). After propensity score adjustment for 17 baseline characteristics, the relative risk of all-cause death remained significantly reduced in ICD/CRT-D carriers (HR 0.30 (0.16-0.57), p<0.0001), even after additional adjusting for CRT-P carrier status (HR 0.27 (0.14-0.52), p<0.0001). 

Conclusion: The initial results from our registry suggest that ICD/CRT-D might be associated with reduced all-cause death in VAD carriers.




Group P-value
Age at implant, years 50±13 56±10 <0.001
Male gender, n (%) 69 (76.7%) 134 (85.9%) 0.07
INTERMACS class 1, n (%) 24 (27.3%) 13 (8.4%) <0.001
INTERMACS class 2, n (%) 24 (27.3%) 33 (21.3%)
INTERMACS class 3, n (%) 19 (21.6%) 61 (39.4%)
INTERMACS class 4-7, n (%) 21 (23.9%) 48 (31.0%)
MCS prior to VAD, n (%) 40 (44.4%) 27 (17.3%) <0.001
VAD type - HMII, n (%) 56 (62.2%) 66 (42.6%) 0.008
VAD type - HW, n (%) 16 (17.8%) 47 (30 3%)
VAD type - HM3, n (%) 15 (16.7%) 41 (26.5%)
VAD type - Other, n (%) 3 (3.3%) 1 (0.6%)
Baseline characteristics of patients according to ICD/CRT-D carrier status.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are